{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:51:26Z","timestamp":1778309486194,"version":"3.51.4"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The Janus kinase\u2013signal transducers and activators of transcription (JAK\u2013STAT) signaling proteins represent a group of intracellular kinase molecules that play a central role in the signaling pathways induced by cytokines, chemokines, and certain growth factors associated with systemic and local inflammation of autoimmune diseases including in Spondyloarthritis (SpA). Here, we will discuss (i) the functional significance of the JAK\u2013STAT kinase cascades in the inflammatory-proliferative processes of SpA and its cellular\/molecular mechanisms (ii) progress in the development of oral synthetic JAK inhibitors (JAKi) and their therapeutic efficacies in SpA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Development JAKi is a fast-moving field in the medical science. Several new-generation JAKi are being identified for psoriatic arthritis and ankylosing spondylitis. It is expected these JAKi likely to have higher potency and less adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Here, we are providing an updated review on the significance of JAK\u2013STAT signaling proteins in SpA with an emphasis on new-generation of JAK\u2013STAT inhibitors for the treatment of SpA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000810","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:09:08Z","timestamp":1621537748000},"page":"348-355","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Janus kinase\u2013signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition"],"prefix":"10.1097","volume":"33","author":[{"given":"Suravi","family":"Raychaudhuri","sequence":"first","affiliation":[{"name":"Depart of Medicine, School of Medicine, Stanford University, Stanford"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karmtej Singh","family":"Cheema","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, Davis, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smriti K.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"VA Sacramento Medical Center, Department of Veterans Affairs, Northern California Healthcare System, Mather"},{"name":"School of Medicine, University of California, Davis, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"VA Sacramento Medical Center, Department of Veterans Affairs, Northern California Healthcare System, Mather"},{"name":"School of Medicine, University of California, Davis, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/BOR.0000000000000399","article-title":"Janus kinase\/signal transducer and activator of transcription pathways in spondyloarthritis","volume":"29","author":"Raychaudhuri","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/art.39458","article-title":"Enthesitis: New Insights into pathogenesis, diagnostic modalities, and treatment","volume":"68","author":"Kehl","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s10067-016-3263-4","article-title":"IL-23\/IL-17 axis in spondyloarthritis-bench to bedside","volume":"35","author":"Raychaudhuri","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2019.02.002","article-title":"Studying interactions between dendritic cells and T cells in vivo","volume":"58","author":"Chudnovskiy","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"R6-20250526","article-title":"Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells","author":"Raychaudhuri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cyto.2018.08.001","article-title":"IL-9 receptor: Regulatory role on FLS and pannus formation","volume":"111","author":"Raychaudhuri","year":"2018","journal-title":"Cytokine"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: JAK-STAT signaling II","volume":"181","author":"Villarino","year":"2020","journal-title":"Cell"},{"issue":"(Suppl 1)","key":"R10-20250526","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"e001374","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the treatment of autoimmune diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J Med Chem"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cyto.2015.12.020","article-title":"IL-9, a local growth factor for synovial T cells in inflammatory arthritis","volume":"79","author":"Kundu-Raychaudhuri","year":"2016","journal-title":"Cytokine"},{"key":"R15-20250526","first-page":"521","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects"},{"issue":"(Suppl. 10)","key":"R16-20250526","article-title":"Blockade of the JAK\/STAT pathway inhibits inflammation and bone formation in two murine models of spondyloarthritis","volume":"70","author":"Maeda","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"15645","DOI":"10.1038\/s41598-018-34026-1","article-title":"Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases","volume":"8","author":"Hammitzsch","year":"2018","journal-title":"Sci Rep"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Investig"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mrfmmm.2010.01.017","article-title":"Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Gen"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.0105-2896.2005.00220.x","article-title":"JAK3, severe combined immunodeficiency, and a new class of immunosuppressive drugs","volume":"203","author":"Pesu","year":"2005","journal-title":"Immunol Rev"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jdermsci.2011.11.011","article-title":"Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGF\u03b2 and STAT3 activating cytokines, IFN\u03b3, IL6, and IL22","volume":"65","author":"Honma","year":"2012","journal-title":"J Dermatol Sci"},{"key":"R26-20250526","first-page":"440","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis","volume":"71","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signaling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"US Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"T Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"R32-20250526","first-page":"694","article-title":"The effect of JAK1\/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib","volume":"37","author":"Choy","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"R34-20250526","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","author":"Mease","year":"2020","journal-title":"Rheum Dis"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"(suppl 10)","key":"R37-20250526","article-title":"Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study [abstract]","volume":"72","author":"Deodhar","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral Janus kinase inhibitor, in moderate-to- severe ulcerative colitis: results from a randomized, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R42-20250526","first-page":"A74","article-title":"Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: data from the phase 2B study U-ACHIEVE","volume":"6","author":"Sandborn","year":"2018","journal-title":"United Europ Gastroenterol J"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the Fitzroy study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"101606","DOI":"10.1016\/j.bpg.2019.03.002","article-title":"Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease","volume":"38-39","author":"Ma","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjd.17149","article-title":"Benefit\u2013risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials","volume":"180","author":"Strober","year":"2019","journal-title":"Br J Dermatol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2B trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med Overseas Ed"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of Baricitinib in patients with active rheumatoid arthritis with over 2\u200ayears median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u200ayears: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl. 1)","key":"R52-20250526","first-page":"638","article-title":"FRI0123: safety profile of Baricitinib for the treatment of Rheumatoid Arthritis up to 8.4\u200ayears: an updated integrated safety analysis","volume":"79","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl. 1)","key":"R53-20250526","first-page":"315","article-title":"THU0187: Safety profile of Upadacitinib up to 3\u200ayears of exposure in patients with Rheumatoid Arthritis","volume":"79","author":"Cohen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in Tofacitinib-treated glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL Balance, an Open-Label, Long-Term Extension Study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol Ther"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:58Z","timestamp":1748294338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000810","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}